Gustavo Velasquez, MD, MPH

Assistant Adjunct Professor

HIV, Infectious Disease, and Global Medicine

Dr. Velásquez is an Assistant Professor of Medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher focused on tuberculosis (TB) therapeutics. Based at the UCSF Center for Tuberculosis (tb.ucsf.edu), he works with the endTB consortium (endTB.org), the SMART4TB consortium (tbcenter.jhu.edu/smart4tb), and the AIDS Clinical Trials Group on Phase 2 and Phase 3 randomized controlled trials evaluating new shortened regimens for drug-susceptible and drug-resistant TB. He attends on the inpatient infectious diseases/HIV consult service and outpatient HIV and TB clinics at San Francisco General Hospital.

Education
2022 - Diversity, Equity, and Inclusion Champion Training, University of California, San Francisco
Fellowship, 2015 - Infectious Diseases, Massachusetts General Hospital and Brigham and Women's Hospital
Residency, 2013 - Internal Medicine and Global Health Equity, Brigham and Women's Hospital
MPH, 2009 - Quantitative Methods and Infectious Disease Epidemiology, Harvard T.H. Chan School of Public Health
MD, 2009 - , Northwestern University Feinberg School of Medicine
BAS, 2004 - , Stanford University
Websites
Publications

  1. Louie JK, Agraz-Lara R, Velásquez GE, Phillips A, Szumowski JD. Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco. Open forum infectious diseases 2024. PMID: 38634108


  2. Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM. Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 38462673


  3. Guglielmetti L*, Khan U*, Velasquez GE*, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, De Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Mucching-Toscano S, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips P, Ruiz J, Salahuddin N, Sanchez-Garavito E, Seung KJ, Ticona E, Trippa L, Vargas D, Wasserman S, Rich ML, Varaine F**, Mitnick CD**. Nine-month, all-oral regimens for rifampin-resistant tuberculosis medRxiv 2024. PMID:


  4. du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. Standards for clinical trials for treating TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023. PMID: 38042969


  5. Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials 2023. PMID: 38037119


  6. McKenna L, Branigan D, Deborggraeve S, Frick M, Furin J, Galarza J, Gebhard A, Gupta S, Kaiser B, de Kruijf-Carter I, Kumar B, Mabote L, Mbenga M, Mirzayev F, Moses GK, Nguyen L, Nyang’wa BT, Pak S, Perrin C, Salazar-Austin N, Sari AH, Seidel S, Velasquez G, Waite R, Waning B, Wares F. An activist’s guide to shorter treatment for drug-resistant tuberculosis 2023. PMID:


  7. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet (London, England) 2023. PMID: 37716363


  8. Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L. Recent advances in the treatment of tuberculosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2023. PMID: 37482332


  9. Rahman RS, Tovar MA, Peinado J, Palomino JS, Ramirez C, Llanos-Zavalaga F, Peralta E, Valderrama G, Ramos Cordova LB, Sanchez Cortez LI, Rodriguez G, LaHood AN, Franke MF, Mitnick CD, Lecca L, Velásquez GE. Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru. Open forum infectious diseases 2023. PMID: 37496609


  10. Velásquez GE, Nahid P. Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis. American journal of respiratory and critical care medicine 2023. PMID: 36630555


  11. Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L. Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru. BMC infectious diseases 2023. PMID: 36732690


  12. Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Velásquez GE, Mitnick CD. Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review. Journal of clinical medicine 2022. PMID: 36233523


  13. Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE. Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru. Microbiology spectrum 2022. PMID: 35867471


  14. Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L. Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru. TO REMOVE 2021. PMID: 33881476


  15. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. TO REMOVE 2021. PMID: 34563240


  16. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts. JAMA health forum 2021. PMID: 35977180


  17. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021 TO REMOVE 2021. PMID:


  18. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO. Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic. TO REMOVE 2021. PMID: 33560423


  19. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu B. SARS-CoV-2 Testing Disparities in Massachusetts. TO REMOVE 2020. PMID: 33173919


  20. Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. TO REMOVE 2020. PMID: 33094118


  21. Rahman R, Davies L, Mohareb AM, Peçanha-Pietrobom PM, Patel NJ, Solomon IH, Meredith DM, Tsai HK, Guenette JP, Bhattacharyya S, Urday S, Velásquez GE. Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report. TO REMOVE 2020. PMID: 32258208


  22. Quispe N, Asencios L, Obregon C, Velásquez GE, Mitnick CD, Lindeborg M, Jave H, Solari L. The fourth national anti-tuberculosis drug resistance survey in Peru. TO REMOVE 2020. PMID: 32127106


  23. Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H. Quantitative assessment of the activity of antituberculosis drugs and regimens. TO REMOVE 2019. PMID: 31144539


  24. Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. TO REMOVE 2019. PMID: 30645140


  25. Velásquez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J. Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group. TO REMOVE 2019. PMID: 30895207


  26. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. TO REMOVE 2018. PMID: 29954183


  27. Velásquez GE, Davies GR, Mitnick CD. Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. TO REMOVE 2018. PMID: 29663947


  28. Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE. A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept. TO REMOVE 2018. PMID: 29532302


  29. Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. TO REMOVE 2017. PMID: 28786798


  30. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. TO REMOVE 2017. PMID: 28559269


  31. Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, Contreras C, Calderon R, Yataco R, Velásquez GE, Tintaya K, Jimenez J, Lecca L, Murray MB. Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts. TO REMOVE 2016. PMID: 27835678


  32. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. TO REMOVE 2016. PMID: 27600032


  33. Diakite I, Mooring EQ, Velásquez GE, Murray MB. Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model. TO REMOVE 2016. PMID: 27509037


  34. Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study. TO REMOVE 2016. PMID: 26831140


  35. Velásquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB. Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. TO REMOVE 2015. PMID: 26129757


  36. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. TO REMOVE 2014. PMID: 24729493


  37. Velásquez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Suárez C, Atwood S, Contreras CC, Shin SS. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. TO REMOVE 2011. PMID: 21392434